Starling Oncology, Inc. 8K

The company entered into a $25 million secured revolving credit facility with SLR Healthcare ABL, maturing in 2029, backed by a first‑priority lien on substantially all assets and governed by comprehensive ABL-style covenants and fees.

On August 20, 2026, Starling Oncology Management, Limited Liability Company (f/k/a TOI Management, LLC) entered into a Credit Agreement with Gemino Healthcare Finance, LLC d/b/a SLR Healthcare ABL establishing a senior secured revolving credit facility of up to $25,000,000, maturing August 20, 2029, secured by a first‑priority perfected security interest in substantially all of the company’s assets (including accounts, deposit accounts, general intangibles and related collateral), with borrowing availability determined by a healthcare receivables-based borrowing base, interest at Term SOFR plus 3.95% with various usage and monitoring fees, mandatory prepayments upon asset sales or casualty proceeds above specified thresholds, and customary affirmative, negative and financial covenants and events of default, including broad restrictions on additional indebtedness, liens, distributions, mergers and affiliate transactions, together with cross‑default and collateral enforcement mechanics typical of an asset-based lending facility in the healthcare sector.

Filing Facts

CIK

1799191

Ticker

-

Form

8K

Source Type

sec

Accession

0001079973-26-001169

Alert Tier

7